Elemental Impurity Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Elemental Impurity Analysis
The author discusses how to manage pending pharmacopeial changes.


Pharmaceutical Technology
Volume 36, Issue 8, pp. 62-64

General Chapter <232>: New limits

USP General Chapter <232> Elemental Impurities—Limits sets out the acceptable levels of 15 elements in final drug products. These limits have been evaluated from toxicological data and are expressed in terms of a daily permissible exposure (DPE) limit. The DPE also takes into consideration the route of administration (e.g., oral, parenteral, or inhalable) with orally administered drugs having a higher permissible limit than parenteral or inhaled drug products. Where elements on the list are known to be present or have the potential to be present then compliance with the specifications must be assessed. The 15 elements addressed in Chapter <232> are based on the International Conference on Harmonization's (ICH) Q3D Elemental Impurities Working Group pre-Stage 2 draft guideline (2).

Chapter <232> covers arsenic, cadmium, mercury, and lead— all elements that are considered ubiquitous and therefore must be assessed in all cases. In addition, the chapter covers iridium, osmium, palladium, platinum, rhodium, ruthenium, chromium, molybdenum, and nickel. The second group of elements may be present in products as a result of being added deliberately, for instance, in the form of a catalyst or through interactions with metal components through the manufacturing process.

Because the ICH Q3D guideline is still being reviewed and is likely to expand to cover more elements, it has been decided that a review of Chapter <232> will happen after the deliberations on ICH Q3D guidelines have been completed. At this stage, the scope of Chapter <232> may be expanded to cover more elements, or an informational chapter may be incorporated to cover elements of low toxicity.

The outdating of long-standing tests

It is fair to point out that the methods of USP General Chapter <231> were developed before the introduction of modern analytical instruments. These methods were easily transferable from one laboratory to another and did not require sophisticated instrumentation or specialized expertise. Hence, a competent laboratory staff member could perform the same techniques with relative ease. The problem was that the methods themselves were flawed, no matter how competent the analyst.

For example, Chapter <231> methods involved subjective visual examination and comparison of the sample solution with a lead standard. Similar to the method of 1905, the compendial methods used a reaction to form the sulphide of any metal ions present and the total metal content was reported against the lead standard response as a limit test.

The validity of this comparison relied on several assumptions, all of which can be questioned. For example, the compendial method assumed that each of the heavy metals in the sample matrix would react in a like manner to lead to form a sulphide species. This assumption applied despite many sulphides being known to be insoluble and despite some elements being known to have a far more intensely colored sulphide than the lead standard against which it was being assessed. Similarly, the compendial method assumed that the reaction kinetics for lead sulphide would be very similar to that of the other metal sulphides and that reaction kinetics were not greatly affected by the sample matrix. A final major and unsafe assumption was that the heating and/or ashing step of the method would have no impact on volatile metals (3).

Work has been carried out that suggests that recovery of mercury can be as little as 2% using the <231> compendial method, which clearly introduces a massive error in the final result (2). Other laboratories have reported similar poor recovery of metals such as tin, selenium, and antimony. These examples are by no means the only reasons to challenge the validity, applicability, and reliability of the compendial methods. In fact, additional chapters for the control of specific metals and other inorganic impurities have been added to USP over the years. Significant among these additions has been USP Chapter <730> Plasma Spectrochemistry, which gave laboratories the opportunity to use techniques such as inductively coupled plasma with either mass spectrometry or atomic emission spectroscopy (ICP–MS and ICP–AES).

The advantage of ICP methods is that they can provide specific detection and quantification for each of the elements specified in Chapter <232>. The subjectivity of the semiquantitative comparison that is required by the compendial methods is eliminated with ICP. The ICP techniques are also quicker in most cases, requiring a smaller sample size and giving a better detection limit for all the elements of interest. The sample preparation method for ICP, for example, is less likely to lead to the loss of the volatile elements.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here